Bictegravir/emtricitabine/tenofovir alafenamide in viremic people with HIV harbouring nucleos(t)ide reverse transcriptase inhibitor resistance‐associated mutations
HIV Medicine · 2026-07 · 27 (7) · 1196-1202
DOI: 10.1111/hiv.70249 ↗Kurz gefasst
Fachartikel in der Zeitschrift HIV Medicine, online erschienen am 28.04.2026. Verfasst von Zheng Qian und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Infectious Disease, The Second Hospital of Nanjing, Nanjing University of Chinese Medicine, Nanjing, China. Hauptthemen laut MEDLINE: HIV Infections, Drug Resistance, Viral, Emtricitabine, HIV-1. Die Arbeit nennt 19 Literaturangaben. Gefördert von: Innovation Center for Infectious Diseases of Jiangsu Province, Jiangsu Provincial Health Commission Medical Research Foundation, General Clinical Trial Project of the Nanjing Medical Science and Technology Development Fund.
Abstract (Originalsprache)
Introduction
Accumulating evidence supports switching virologically suppressed people with HIV (PWH) harbouring nucleoside reverse transcriptase inhibitor (NRTI) resistance‐associated mutations (RAMs) to bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF). However, real‐world data on initiating B/F/TAF in individuals with NRTI RAMs and ongoing viremia remain limited.
Methods
We retrospectively included adult PWH treated at the Second Hospital of Nanjing between June 2020 and November 2024 who had at least one NRTI RAM and an HIV‐1 RNA ≥200 copies/mL at B/F/TAF initiation. The primary outcome was virological suppression at 12 months (HIV‐1 RNA
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Infectious Disease, The Second Hospital of Nanjing, Nanjing University of Chinese Medicine, Nanjing, China.
- School of Public Health, Nanjing Medical University, Nanjing, China.
- Clinical Research Center, The Second Hospital of Nanjing, Nanjing University of Chinese Medicine, Nanjing, China.
ORCID-Profile: Zheng Qian
Förderung
- Innovation Center for Infectious Diseases of Jiangsu Province
- Jiangsu Provincial Health Commission Medical Research Foundation
- General Clinical Trial Project of the Nanjing Medical Science and Technology Development Fund
Zitieren
APA
Qian, Z., Liu, A., Yang, J., Qin, J., Chen, W., Ge, Y., Zhong, Y., Wei, H., Chen, Y., & Hu, Z. (2026). Bictegravir/emtricitabine/tenofovir alafenamide in viremic people with HIV harbouring nucleos(t)ide reverse transcriptase inhibitor resistance‐associated mutations. HIV Medicine, 27(7), 1196-1202. https://doi.org/10.1111/hiv.70249
Vancouver
Qian Z, Liu A, Yang J, Qin J, Chen W, Ge Y, et al. Bictegravir/emtricitabine/tenofovir alafenamide in viremic people with HIV harbouring nucleos(t)ide reverse transcriptase inhibitor resistance‐associated mutations. HIV Medicine. 2026;27(7):1196-1202. doi:10.1111/hiv.70249
BibTeX
@article{Qian2026,
author = {Qian, Zheng and Liu, Anni and Yang, Jinjin and Qin, Jiamin and Chen, Wei and Ge, You and Zhong, Yandan and Wei, Hongxia and Chen, Yaling and Hu, Zhiliang},
title = {Bictegravir/emtricitabine/tenofovir alafenamide in viremic people with HIV harbouring nucleos(t)ide reverse transcriptase inhibitor resistance‐associated mutations},
journal = {HIV Medicine},
year = {2026},
volume = {27},
number = {7},
pages = {1196--1202},
doi = {10.1111/hiv.70249}
}
EUVIMED